[Perinatal encephalopathy sequelae identified by a neurobehavioral scale in one year old infants]

OBJECTIVE

to identify neurodevelopmental sequelae in one year old infants with perinatal encephalopathy utilizing the neurobehavioral scale named Vanedela.

METHODS

a cohort of 75 newborns with perinatal encephalopathy was assessed with a neurobehavioral follow-up scale at age of 1, 4, 8 and 12 months. A distinction was made between functional, structural and combined encephalopathy. Two groups of neurodevelopmental outcome at one year were identified: with or without sequelae. Nonparametric statistics was used.

RESULTS

infants with functional encephalopathy had the best scores, followed by those with structural encephalopathy, while infants with a combined encephalopathy had the lowest scores. At one year of age, the group with neurobehavioral sequelae exhibited the lowest scores and retarded growth. At the same age, the group with functional encephalopathy exhibited no neurobehavioral sequelae, and reached better scores and growth.

CONCLUSIONS

the neurobehavioral follow-up scale is able to identify the neurodevelopmental sequelae at the age of one year in infants with perinatal encephalopathy. The application of Vanedela in the clinical field requires of little time, its results are trustworthy and very useful for the neurobehavioral follow-up assessment.

[Peroxisomal D-bifunctional enzyme deficiency. A case report]

Newborn was referred with diagnosis of neonatal epilepsy. Medical team could suspect and confirm D-bifunctional peroxisomal enzymatic deficiency diagnosis. It was made by family antecedents, severe neonatal hypotonia, uncontrolled neonatal seizures, craniofacial dysmorphic features, psychomotor retardation, neuronal migration defect and a positive peroxisomal panel. The full study in skin fibroblasts involved enzyme analysis, complementation studies and DNA analysis. The accumulation of very long chain fatty acids, partial deficiency in phytanic acid oxidation, and abnormal morphology of peroxisomes was consistent with a defect in peroxisomal fatty acid oxidation, involving D-bifunctional protein. It is very important to make a diagnosis of this innate error of metabolism in order to give preconceptional genetic counseling, to identify recurrence risk and to perform mutation analysis for the D-bifunctional protein gene, and to offer the prenatal diagnosis.

[Blood levels of phenytoin. Pharmacokinetics and individualization of dosages in controlled children with crises and with persistence of crises]

The pharmacokinetics of phenytoin was evaluated using the Michaelis-Menten technique in children with seizures seen at the Outpatient Ward, in order to adjust their medication dosages based on a clinical-pharmacological relation. The children were divided into two groups: Group A (controlled seizures) and group B (persistent seizures). Each group of children were orally given 7 mg/kg of phenytoin. Their serum levels were measured using enzymatic immunoassay at one, two, four, eight and 12 hours after taking the medication. There was a significant correlation (P less than 0.05) between the average saturation constant (Km) and the maximum speed (Vmax) with age and the doses administered in group A, which showed a lesser metabolic capacity than group B. There was also a significant correlation (P less than 0.05) when predicting the levels in each group. Clinically, the patients group A were controlled while those in group B witnessed a lesser frequency and intensity of the seizures in six patients, two were controlled and two others remained the same. The data shows a clinical-pharmacological correlation in children difficult to control, and improves the dosaging criteria used each individuals needs.